Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Regencell Bioscience Holdings Ltd (RGC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: RGC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 2041.82% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.74B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 73202 | Beta 2.62 | 52 Weeks Range 3.03 - 950.00 | Updated Date 06/14/2025 |
52 Weeks Range 3.03 - 950.00 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.11% | Return on Equity (TTM) -43.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 195912836 | Price to Sales(TTM) - |
Enterprise Value 195912836 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -44.58 | Shares Outstanding 13012900 | Shares Floating 786888 |
Shares Outstanding 13012900 | Shares Floating 786888 | ||
Percent Insiders 93.84 | Percent Institutions 0.07 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Regencell Bioscience Holdings Ltd
Company Overview
History and Background
Regencell Bioscience Holdings Ltd, founded in 2019, focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of diseases such as ADHD and other neurocognitive disorders. It has primarily focused on research and development.
Core Business Areas
- Research and Development: Focuses on TCM formulas for neurocognitive disorders, including ADHD. Conducts clinical trials and studies to validate efficacy and safety.
- Potential Commercialization: Aims to commercialize TCM formulas through licensing, partnerships, or direct sales if clinical trials are successful and regulatory approval is obtained.
Leadership and Structure
The leadership team is relatively small and centered around the CEO. The organizational structure appears to be lean, reflecting the early-stage nature of the company.
Top Products and Market Share
Key Offerings
- RGC-COV19: A TCM formula under development for treating COVID-19. Clinical trials have been conducted, but commercialization is uncertain. Market share is currently zero as it's not yet approved for sale. Competitors include pharmaceutical companies with approved COVID-19 treatments (e.g., Pfizer, Merck).
- ADHD Treatment (TCM Formula): A TCM formula under development for ADHD treatment. Currently in research and development phase. Market share is currently zero. Competitors include pharmaceutical companies with approved ADHD medications (e.g., Novartis, Eli Lilly).
Market Dynamics
Industry Overview
The industry involves the development and commercialization of pharmaceutical products and TCM. The pharmaceutical market is highly competitive and regulated. The TCM market is growing but faces challenges related to scientific validation and regulatory acceptance.
Positioning
Regencell is a small player in the pharmaceutical and TCM markets. Its competitive advantage, if any, relies on the potential efficacy and acceptance of its TCM formulas.
Total Addressable Market (TAM)
The global ADHD therapeutics market size was valued at USD 13.7 billion in 2022 and is expected to reach USD 25.0 billion by 2032. Regencell's position depends on successful trials and commercialization.
Upturn SWOT Analysis
Strengths
- Focus on TCM
- Novel TCM formula development
- Potential for alternative treatment options
Weaknesses
- Early-stage company
- Limited financial resources
- Reliance on successful clinical trials
- Dependence on single or small number of treatments
Opportunities
- Growing interest in TCM
- Potential partnerships with pharmaceutical companies
- Expansion into new markets
- Evolving regulatory landscape for TCM
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Clinical trial failures
- Lack of market acceptance of TCM
- Funding risks
Competitors and Market Share
Key Competitors
- LLY
- NVS
- PFE
- MRK
Competitive Landscape
Regencell faces significant disadvantages compared to established pharmaceutical companies. Its success hinges on differentiating its TCM formulas and gaining market acceptance.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to being an early-stage R&D company.
Future Projections: Future growth is entirely dependent on successful clinical trials, regulatory approvals, and commercialization of its TCM formulas. Analyst estimates are speculative.
Recent Initiatives: Recent initiatives focus on ongoing clinical trials for RGC-COV19 and the ADHD treatment.
Summary
Regencell Bioscience Holdings Ltd is a very early-stage pharmaceutical company with a high-risk, high-reward profile. Its success depends on the successful development and commercialization of its TCM formulas, which faces regulatory and market acceptance hurdles. The company has limited financial resources and significant competition from established pharmaceutical companies. Investment in Regencell is highly speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market data is indicative and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regencell Bioscience Holdings Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-16 | Founder, Chairman & CEO Mr. Yat-Gai Au | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 12 | |
Full time employees 12 | |||
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.